interferon beta

Summary

Summary: One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.

Top Publications

  1. ncbi Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3
    Rashu B Seth
    Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cell 122:669-82. 2005
  2. ncbi IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway
    Katherine A Fitzgerald
    Division of Infectious Disease and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Nat Immunol 4:491-6. 2003
  3. ncbi IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
    Taro Kawai
    Exploratory Research for Advanced Technology, Japan Science and Technology Agency
    Nat Immunol 6:981-8. 2005
  4. ncbi RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates
    Andreas Pichlmair
    Immunobiology Laboratory, Cancer Research UK, London Research Institute, London WC2A 3PX, UK
    Science 314:997-1001. 2006
  5. ncbi 5'-Triphosphate RNA is the ligand for RIG-I
    Veit Hornung
    Division of Clinical Pharmacology, Department of Internal Medicine, University of Munich, 80336 Munich, Germany
    Science 314:994-7. 2006
  6. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
  7. ncbi Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
    Etienne Meylan
    Department of Biochemistry, University of Lausanne, BIL Biomedical Research Center, Chemin des Boveresses 155, CH 1066 Epalinges, Switzerland
    Nature 437:1167-72. 2005
  8. ncbi Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers
    Jacqueline Palace
    DM, Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Level 3 West Wing, Oxford OX3 9DU, England
    Arch Neurol 67:1016-7. 2010
  9. ncbi A weak signal for strong responses: interferon-alpha/beta revisited
    T Taniguchi
    Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nat Rev Mol Cell Biol 2:378-86. 2001
  10. ncbi VISA is an adapter protein required for virus-triggered IFN-beta signaling
    Liang Guo Xu
    Department of Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, Colorado 80206, USA
    Mol Cell 19:727-40. 2005

Detail Information

Publications303 found, 100 shown here

  1. ncbi Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3
    Rashu B Seth
    Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cell 122:669-82. 2005
    ..The transmembrane domain targets MAVS to the mitochondria, implicating a new role of mitochondria in innate immunity...
  2. ncbi IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway
    Katherine A Fitzgerald
    Division of Infectious Disease and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Nat Immunol 4:491-6. 2003
    ..Thus, IKKepsilon and TBK1 have a pivotal role in coordinating the activation of IRF3 and NF-kappaB in the innate immune response...
  3. ncbi IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
    Taro Kawai
    Exploratory Research for Advanced Technology, Japan Science and Technology Agency
    Nat Immunol 6:981-8. 2005
    ..Knockdown' of IPS-1 by small interfering RNA blocked interferon induction by virus infection. Thus, IPS-1 is an adaptor involved in RIG-I- and Mda5-mediated antiviral immune responses...
  4. ncbi RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates
    Andreas Pichlmair
    Immunobiology Laboratory, Cancer Research UK, London Research Institute, London WC2A 3PX, UK
    Science 314:997-1001. 2006
    ....
  5. ncbi 5'-Triphosphate RNA is the ligand for RIG-I
    Veit Hornung
    Division of Clinical Pharmacology, Department of Internal Medicine, University of Munich, 80336 Munich, Germany
    Science 314:994-7. 2006
    ....
  6. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
    b>Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses...
  7. ncbi Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
    Etienne Meylan
    Department of Biochemistry, University of Lausanne, BIL Biomedical Research Center, Chemin des Boveresses 155, CH 1066 Epalinges, Switzerland
    Nature 437:1167-72. 2005
    ..Cardif thus functions as an adaptor, linking the cytoplasmic dsRNA receptor RIG-I to the initiation of antiviral programmes...
  8. ncbi Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers
    Jacqueline Palace
    DM, Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Level 3 West Wing, Oxford OX3 9DU, England
    Arch Neurol 67:1016-7. 2010
    To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody levels increased following treatment with interferon beta.
  9. ncbi A weak signal for strong responses: interferon-alpha/beta revisited
    T Taniguchi
    Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nat Rev Mol Cell Biol 2:378-86. 2001
    ..What is the purpose of the constitutive weak interferon-alpha/beta signal?..
  10. ncbi VISA is an adapter protein required for virus-triggered IFN-beta signaling
    Liang Guo Xu
    Department of Immunology, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, Colorado 80206, USA
    Mol Cell 19:727-40. 2005
    ..These findings suggest that VISA is critically involved in both virus-triggered TLR3-independent and TLR3-mediated antiviral IFN signaling...
  11. ncbi mda-5, but not RIG-I, is a common target for paramyxovirus V proteins
    Kay Childs
    Division of Basic Medical Sciences, St George s, University of London, London SW17 0RE, UK
    Virology 359:190-200. 2007
    ..In contrast, the V proteins do not bind to the related RNA helicase RIG-I and do not inhibit its activity. The relative contributions of mda-5 and RIG-I to IFN-beta induction are discussed...
  12. ncbi TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
    Michaela U Gack
    Department of Microbiology and Molecular Genetics and Tumor Virology Division, New England Primate Research Center, Harvard Medical School, 1 Pine Hill Drive, Southborough, Massachusetts 01772, USA
    Nature 446:916-920. 2007
    ..Thus, we demonstrate that TRIM25 E3 ubiquitin ligase induces the Lys 63-linked ubiquitination of RIG-I, which is crucial for the cytosolic RIG-I signalling pathway to elicit host antiviral innate immunity...
  13. pmc Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA
    Takeshi Saito
    Department of Immunology, University of Washington School of Medicine, Seattle, Washington 98195 7650, USA
    Nature 454:523-7. 2008
    ....
  14. pmc A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice
    Wen Jun Liu
    School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Australia
    J Virol 80:2396-404. 2006
    ....
  15. pmc Small self-RNA generated by RNase L amplifies antiviral innate immunity
    Krishnamurthy Malathi
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nature 448:816-9. 2007
    ..Our results indicate that RNase L has an essential role in the innate antiviral immune response that relieves the requirement for direct sensing of non-self RNA...
  16. ncbi Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway
    Masahiro Yamamoto
    Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, 3 1 Yamada oka, Suita Osaka 565 0871, Japan
    Science 301:640-3. 2003
    ..These findings demonstrate that TRIF is essential for TLR3- and TLR4-mediated signaling pathways facilitating mammalian antiviral host defense...
  17. ncbi Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56
    Fulvia Terenzi
    Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Biol Chem 281:34064-71. 2006
    ..Thus, although similar in structure, the human P54 and P56 proteins are induced differently and function differently...
  18. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    To conduct systematic long-term follow-up (LTFU) of patients in the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) study to provide up to 8 years of safety, clinical and MRI ..
  19. ncbi Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes
    B J Barnes
    Oncology Center and the Department of Molecular Biology and Genetics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Biol Chem 276:23382-90. 2001
    ..These data indicate that multiple signaling pathways induced by infection may be differentially recognized by members of the IRF family and modulate transcription of individual IFNA genes in a virus and cell type-specific manner...
  20. ncbi Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study
    Hillel Panitch
    University of Vermont, College of Medicine, Burlington 05401, USA
    Neurology 63:1788-95. 2004
    To evaluate the efficacy and safety of interferon beta-1b (IFNbeta-1b) in subjects with secondary progressive multiple sclerosis (SPMS).
  21. ncbi Recognition of cytosolic DNA activates an IRF3-dependent innate immune response
    Daniel B Stetson
    Howard Hughes Medical Institute, Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Immunity 24:93-103. 2006
    ..These findings define an innate immune response to DNA linked to type I interferon production...
  22. pmc Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1
    Atsushi Iwai
    Department of Bioresources, hHokkaido University Research Center for Zoonosis Control, North 20, West 10 Kita ku, Sapporo, Hokkaido 001 0020, Japan
    J Biol Chem 285:32064-74. 2010
    ..These findings demonstrate that the viral polymerase plays an important role for regulating host anti-viral response through the binding to IPS-1 and inhibition of IFNβ production...
  23. ncbi Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 8:987-97. 2009
    ..emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome...
  24. ncbi Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo
    M G Wathelet
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    Mol Cell 1:507-18. 1998
    ..These observations provide a unique example of the coordinate activation of multiple transcriptional activator proteins and their highly cooperative assembly into a transcriptional enhancer complex in vivo...
  25. ncbi Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
    B K Kleinschmidt-Demasters
    Department of Pathology, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 353:369-74. 2005
    ..received 37 doses of natalizumab (300 mg every four weeks) as part of a clinical trial of natalizumab and interferon beta-1a...
  26. ncbi Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection
    Khuong B Nguyen
    Deparment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
    J Immunol 169:4279-87. 2002
    ....
  27. pmc An atomic model of the interferon-beta enhanceosome
    Daniel Panne
    The Jack and Eileen Connors Structural Biology Laboratory, Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Howard Hughes Medical Institute, 250 Longwood Avenue, Boston, MA 02115, USA
    Cell 129:1111-23. 2007
    ..Contacts with virtually every nucleotide pair account for the evolutionary invariance of the enhancer sequence...
  28. ncbi Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer
    K Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 32:228-32. 2000
    ..0004). In conclusion, intermittent administration of IFN suppressed tumor recurrence after treatment with surgery or ethanol injection in patients with HCV-related chronic liver disease...
  29. pmc Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
    H Li
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Gene Ther 17:550-8. 2010
    ..To increase the potency of oncolytic measles viruses (MVs) for mesothelioma therapy, we inserted the interferon beta (IFNbeta) gene alone or with the human thyroidal sodium iodide symporter (NIS) gene into attenuated MV of the ..
  30. ncbi Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis
    Esther Byun
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0435, USA
    Arch Neurol 65:337-44. 2008
    To identify promising candidate genes linked to interindividual differences in the efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS)...
  31. ncbi Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination
    Yoko Warabi
    Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
    J Neurol Sci 252:57-61. 2007
    To evaluate the effect of interferon beta-1b (IFNB-1b) on multiple sclerosis (MS) with severe optic nerve and spinal cord demyelination, we examined the relationship between IFNB-1b treatment outcome and the clinical and genetic ..
  32. ncbi Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  33. pmc Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions
    L Farkas
    Laboratory for Immunohistochemistry and Immunopathology, University of Oslo, Rikshospitalet, Oslo, Norway
    Am J Pathol 159:237-43. 2001
    ..Together, our findings suggested that P-DCs are an important source of IFN-alpha/beta in cutaneous LE lesions and may therefore be of pathogenic importance...
  34. pmc Neurons produce type I interferon during viral encephalitis
    Sophie Delhaye
    Microbial Pathogenesis Unit, Université catholique de Louvain and Christian de Duve Institute of Cellular Pathology, MIPA VIRO 74 49, 74, Avenue Hippocrate, B 1200 Brussels, Belgium
    Proc Natl Acad Sci U S A 103:7835-40. 2006
    ..Our data show that, in vivo, neurons take an active part to the antiviral defense by being both IFN-alpha/beta producers and responders...
  35. ncbi Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?
    F Patti
    Dept of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy
    J Neurol 255:1250-3. 2008
    ..Aim of this study is to evaluate risks of the administration of INFbeta related not only to the foetus, but also to children development up to 12-months developmental milestones...
  36. ncbi Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  37. ncbi Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 52:400-6. 2002
    ..treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta. We studied 252 patients with a follow-up of more than 2 years...
  38. ncbi Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy
    G M Galeazzi
    Consultation Liaison Psychiatry Service, Department of Neuroscience TCR, Section of Psychiatry, University of Modena and Reggio Emilia, Via del Pozzo 71, I 41100 Modena, Italy
    Neurol Sci 26:255-62. 2005
    ..67). Risk factors for depression were female sex and severity of disability, but not therapy with interferon beta or longer duration of illness...
  39. ncbi Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers
    Jan Hilpert
    Clinical Pharmacology, Bayer Schering Pharma AG, Berlin, Germany
    J Neuroimmunol 199:115-25. 2008
    Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking...
  40. ncbi Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    Daniel Wynn
    Consultants in Neurology Multiple Sclerosis Center, Northbrook, IL, USA
    Lancet Neurol 9:381-90. 2010
    ..We aimed to assess whether daclizumab reduces disease activity in patients with active relapsing multiple sclerosis who are receiving interferon beta treatment.
  41. ncbi Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial
    Mansoureh Togha
    Sina Hospital, Tehran, Iran
    Mult Scler 16:848-54. 2010
    This study was conducted to evaluate the effect of simvastatin (40 mg/day) as an adjuvant therapy to interferon beta (IFNb 1a, 30 microg once weekly) in relapsing-remitting multiple sclerosis patients, compared with placebo.
  42. ncbi Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
    A Sominanda
    Department of Clinical Neuroscience, Division of Neurology R54, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
    Mult Scler 13:208-14. 2007
    Development of neutralizing antibodies (NAbs) reduces the clinical efficacy of interferon beta (IFNbeta) treatment in multiple sclerosis (MS) patients...
  43. ncbi Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction
    Shinji Ohno
    Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812 8582, Japan
    J Gen Virol 85:2991-9. 2004
    ..Taken together, our results indicate that both the N- and C-terminal regions contribute to the IFN-antagonist activity of the MV V protein...
  44. ncbi A comparative study of the relative bioavailability of different interferon beta preparations
    F Deisenhammer
    Department of Neurology, University of Innsbruck, Austria
    Neurology 54:2055-60. 2000
    Three different recombinant interferon beta (IFNbeta) preparations are currently available for the treatment of MS, two IFNbeta-1a products (Rebif and Avonex) and one IFNbeta-1b product (Betaferon)...
  45. ncbi Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction
    M Sato
    Department of Immunology, Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Japan
    Immunity 13:539-48. 2000
    ..These results demonstrate the essential and distinct roles of thetwo factors, which together ensure the transcriptional efficiency and diversity of IFN-alpha/beta genes for the antiviral response...
  46. pmc Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence
    Brian C Keller
    Department of Microbiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9048, USA
    J Virol 80:9424-34. 2006
    ..Consistent with this finding, the virulence of MAD78 was unmasked upon infection of mice lacking IFNAR. Thus, control of the innate host response and IFN actions is a key feature of WNV pathogenesis and replication fitness...
  47. ncbi Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence
    Akinori Takaoka
    Department of Immunology, Faculty of Medicine and Graduate School of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nature 424:516-23. 2003
    ..Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications...
  48. pmc Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
    David H Kirn
    Jennerex Biotherapeutics, San Francisco, California, United States of America
    PLoS Med 4:e353. 2007
    ..We report the construction and preclinical testing of this virus...
  49. pmc Multiple anti-interferon actions of the influenza A virus NS1 protein
    Georg Kochs
    Department of Virology, University of Freiburg, D 79008 Freiburg, Germany
    J Virol 81:7011-21. 2007
    ..Our results demonstrate the capacity of FLUAV NS1 to suppress the antiviral host defense at multiple levels and the existence of strain-specific differences that may modulate virus pathogenicity...
  50. pmc Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus
    Masaki Mibayashi
    Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Virol 81:514-24. 2007
    ..Our results indicate that, in addition to sequestering dsRNA, the NS1 of influenza A virus binds to RIG-I and inhibits downstream activation of IRF-3, preventing the transcriptional induction of IFN-beta...
  51. ncbi Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis
    Xin Zhang
    Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Clin Neurol Neurosurg 112:641-5. 2010
    ..Our results have identified novel therapeutic mechanisms of IFNbeta, which inhibit Th17 cell differentiation in the context of the autoimmune response in MS...
  52. pmc RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway
    Yu Hsin Chiu
    Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9148, USA
    Cell 138:576-91. 2009
    ..These results suggest that RNA Pol-III is a cytosolic DNA sensor involved in innate immune responses...
  53. ncbi Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system
    Marco Prinz
    Department of Neuropathology, University of Freiburg, D 79106 Freiburg, Germany
    Immunity 28:675-86. 2008
    ..Here, we demonstrate elevated interferon beta concentrations in the CNS, but not blood, of mice with experimental autoimmune encephalomyelitis (EAE), a ..
  54. pmc Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity
    Xiao Dong Li
    Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9148, USA
    Proc Natl Acad Sci U S A 102:17717-22. 2005
    ....
  55. ncbi Rac1 and PAK1 are upstream of IKK-epsilon and TBK-1 in the viral activation of interferon regulatory factor-3
    Christina Ehrhardt
    Institute of Molecular Medicine, Heinrich Heine Universitat, Universitatsstrasse 1, D 40225, Duesseldorf, Germany
    FEBS Lett 567:230-8. 2004
    ..Furthermore, both Rac1 and PAK1 regulate the recently described IRF-3 activators, I kappa B kinase- and TANK-binding kinase-1, establishing a first canonical virus-induced IRF-3 activating pathway...
  56. pmc The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter
    J Andrejeva
    School of Biology, Biomolecular Sciences Building, North Haugh, University of St Andrews, Fife KY16 9TS, United Kingdom
    Proc Natl Acad Sci U S A 101:17264-9. 2004
    ....
  57. ncbi Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN
    N Kadowaki
    Department of Immunobiology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304, USA
    J Immunol 166:2291-5. 2001
    ....
  58. ncbi Defining interferon beta response status in multiple sclerosis patients
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 56:548-55. 2004
    ..MRI classification may facilitate rational therapeutic decisions, better clinical trial designs, and studies correlating biomarkers with therapeutic response...
  59. pmc Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus
    Jörg Schlender
    Max von Pettenkofer Institute and Gene Center, Feodor Lynen Str 25, D 81377 Munich, Germany
    J Virol 79:5507-15. 2005
    ..The capacity of RSV and measles virus of human PDC to shut down IFN production should contribute to the characteristic features of these viruses, such as Th2-biased immune pathology, immune suppression, and superinfection...
  60. ncbi Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA
    Hideyuki Yoshida
    Department of Genetics, Osaka University Medical School, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
    Nat Immunol 6:49-56. 2005
    ....
  61. ncbi Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Edifici Escola d Infermeria 2 feminine planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:972-8. 2009
    b>Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS)...
  62. pmc Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation
    Kristopher Clark
    MRC Protein Phosphorylation Unit, College of Life Sciences, Sir James Black Centre, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom
    J Biol Chem 284:14136-46. 2009
    ....
  63. pmc A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients
    C Milanese
    Centro Regionale per la Cura della Sclerosi Multipla, Istituto Nazionale Neurologico C Besta, Milan, Italy
    J Neurol Neurosurg Psychiatry 74:1689-92. 2003
    b>Interferon beta 1b (Betaferon) and 1a (Avonex) were licensed in Italy for treating relapsing-remitting multiple sclerosis in February 1996 and August 1997, respectively.
  64. ncbi RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta
    Hiroshi Takayanagi
    Department of Immunology, Faculty of Medicine and Graduate School of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo 113 0033, Japan
    Nature 416:744-9. 2002
    ..Our study places the IFN-beta system in a new context, and may offer a molecular basis for the treatment of bone diseases...
  65. pmc Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection
    L P Cousens
    Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912, USA
    J Exp Med 189:1315-28. 1999
    ....
  66. pmc Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses
    J M McNally
    Department of Pathology, Program in Immunology and Virology, University of Massachusetts Medical School, 55 Lake Ave. N, Worcester, MA 01655, USA
    J Virol 75:5965-76. 2001
    ..Apoptotic attrition of bystander T cells may make room for the antigen-specific expansion of T cells during infection and may, in part, account for the loss of T-cell memory that occurs when the host undergoes subsequent infections...
  67. ncbi TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis
    Klaus Peter Wandinger
    Institute of Neuroimmunology, Charite University Hospital, Schumannstrasse 20 21, 10117, Berlin, Germany
    Lancet 361:2036-43. 2003
    Many patients with multiple sclerosis do not respond to interferon beta, which is widely used as an immunomodulatory treatment in this disease...
  68. ncbi Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity
    D Hesse
    Danish Multiple Sclerosis Research Center, Department of Neurology 2082, Copenhagen University Hospital Rigshospitalet, Denmark
    Neurology 73:372-7. 2009
    ..In a cohort study, we measured gene expression by gene chip analysis in NAb-negative and NAb-positive patients to test that hypothesis...
  69. pmc Induction of iNOS expression and antimicrobial activity by interferon (IFN)-beta is distinct from IFN-gamma in Burkholderia pseudomallei-infected mouse macrophages
    P Utaisincharoen
    Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand
    Clin Exp Immunol 136:277-83. 2004
    ....
  70. pmc STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition
    Aparna Ramachandran
    Department of Medicine, Northwestern University, Evanston, Illinois, USA
    J Virol 82:8330-8. 2008
    ..These findings clearly define the molecular determinants for measles virus IFN evasion and validate specific targets as candidates for therapeutic intervention...
  71. ncbi Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes
    Kui Li
    Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas 77555 1019, USA
    J Biol Chem 280:16739-47. 2005
    ..We conclude that hepatocytes contain two distinct antiviral signaling pathways leading to expression of type I IFNs, one dependent upon TLR3 and the other dependent on RIG-I, with little cross-talk between these pathways...
  72. pmc REUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-I
    Dong Gao
    Key Laboratory of Cell Proliferation and Differentiation Ministry of Education, College of Life Sciences, Peking University, Beijing, China
    PLoS ONE 4:e5760. 2009
    ..These findings suggest that REUL is an E3 ubiquitin ligase of RIG-I and specifically stimulates RIG-I-mediated innate antiviral activity...
  73. ncbi Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
    L D Jacobs
    Department of Neurology, State University of New York School of Medicine at Buffalo and Buffalo General Hospital, 14203, USA
    N Engl J Med 343:898-904. 2000
    Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value.
  74. ncbi Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis
    Katarzyna Biernacki
    Neuroimmunology Unit and McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University
    Arch Neurol 62:563-8. 2005
    b>Interferon beta therapy has been shown to reduce the rate of clinical relapse and the frequency of magnetic resonance imaging-defined T2- weighted lesions in patients with multiple sclerosis (MS)...
  75. pmc The wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-beta production
    Tina Mahieu
    Department for Molecular Biomedical Research, Flanders Interuniversity Institute for Biotechnology and Ghent University, Technologiepark 927, B 9052 Ghent, Belgium
    Proc Natl Acad Sci U S A 103:2292-7. 2006
    ..In contrast to TLR4-deficient mice, SPRET/Ei mice resist both LPS and sepsis induced with Klebsiella pneumoniae...
  76. ncbi Double-stranded RNA induces pancreatic beta-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways
    Zeynep Dogusan
    Laboratory of Experimental Medicine, Universite Libre de Bruxelles, Route de Lennik, 808, CP 618, B 1070 Brussels, Belgium
    Diabetes 57:1236-45. 2008
    ..We presently investigated the mediators and downstream effectors of dsRNA-induced beta-cell death...
  77. pmc SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways
    Jun Huang
    College of Life Sciences, Peking University, Beijing, China
    EMBO J 24:4018-28. 2005
    ..These findings suggest that SIKE is a physiological suppressor of IKKepsilon and TBK1 and plays an inhibitory role in virus- and TLR3-triggered IRF-3 but not NF-kappaB activation pathways...
  78. ncbi VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
    David F Stojdl
    Ottawa Regional Cancer Centre Research Laboratories, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
    Cancer Cell 4:263-75. 2003
    ..While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority of treated animals when delivered systemically...
  79. pmc Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms
    Stephane Daffis
    Department of Medicine, Washington University School of Medicine, St Louis Missouri, United States of America
    PLoS Pathog 3:e106. 2007
    ..Collectively, our data suggest that cell-specific IRF-3 responses protect against WNV infection through both IFN-dependent and -independent programs...
  80. ncbi Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses
    roy W Beck
    CHAMPS Analysis Center, Jaeb Center for Health Research, Tampa, FL 33613, USA
    Ann Neurol 51:481-90. 2002
    The objective of this work was to assess the effect of interferon beta-1a (Avonex) on the rate of development of clinically definite multiple sclerosis and brain magnetic resonance imaging changes in subgroups based on type of presenting ..
  81. ncbi Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations
    A Bertolotto
    Divisione Universitaria di Neurologia, Ospedale San Luigi, Regione Gonzole 10, 10043 Orbassano TO, Italy
    Immunopharmacology 48:95-100. 2000
    ..387 samples of 111 multiple sclerosis (MS) patients treated with one of the three commercial preparations of interferon beta (IFNbeta)...
  82. ncbi Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response
    P K Coyle
    Department of Neurology, SUNY at Stony Brook, New York 11794, USA
    Mult Scler 8:2-9. 2002
    ....
  83. ncbi Type I IFN-beta gene therapy suppresses cardiac CD8+ T-cell infiltration during autoimmune myocarditis
    Emmalene J Bartlett
    Division of Health Sciences, Western Australian Biomedical Research Institute, Murdoch University, WA 6150, Australia
    Immunol Cell Biol 82:119-26. 2004
    ..Thus, treatment with IFN-beta administered prophylactically to high-risk patients in acquiring CMV infection may reduce the development of chronic autoimmune myocarditis...
  84. pmc The effect of immunomodulatory treatment on multiple sclerosis fatigue
    L M Metz
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Neurol Neurosurg Psychiatry 75:1045-7. 2004
    ..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...
  85. ncbi Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study
    Annie W Chiu
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892 1400, USA
    Arch Neurol 66:39-43. 2009
    To investigate the heterogeneity in magnetic resonance image (MRI) patterns of response to interferon beta across patients with multiple sclerosis or within an individual patient over time.
  86. pmc Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
    O Andersen
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Goteborg, Goteborg, Sweden
    J Neurol Neurosurg Psychiatry 75:706-10. 2004
    ....
  87. ncbi Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:1136-41. 2008
    ....
  88. ncbi Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta
    Ann Charlotte Iversen
    Division of Molecular Immunology, La Jolla Institute for Allergy and Immunology, San Diego, CA 92121, USA
    J Immunol 175:7568-74. 2005
    ..These results highlight an efficient mechanism used by NK cells to activate IFN-beta expression in the infected target cell that contributes to the arrest of virion production and virus spread without cellular elimination...
  89. ncbi TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
    Roberto Baccala
    The Scripps Research Institute, Department of Immunology, La Jolla, California 93037, USA
    Nat Med 13:543-51. 2007
    ....
  90. ncbi The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b
    J Brettschneider
    Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany
    J Neuroimmunol 133:193-7. 2002
    ..In patients with PPMS, sCD14 levels were determined before and after treatment with interferon beta (IFNB). In both PPMS and in RRMS, sCD14 levels were significantly elevated compared to healthy controls...
  91. pmc Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production
    Frank O Nestle
    Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland
    J Exp Med 202:135-43. 2005
    ..These findings uncover a novel innate immune pathway for triggering a common human autoimmune disease and suggest that PDCs and PDC-derived IFN-alpha represent potential early targets for the treatment of psoriasis...
  92. pmc Enhanceosome formation over the beta interferon promoter underlies a remote-control mechanism mediated by YY1 and YY2
    Martin Klar
    German Research Center for Biotechnology GBF, RDIF Epigenetic Regulation, Mascheroder Weg 1, 38124 Braunschweig, Germany
    Mol Cell Biol 25:10159-70. 2005
    ..Differences between the human and murine control regions will be described...
  93. ncbi Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
    Massimo Filippi
    Neuroimaging Research Unit, Department of Neurology, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Lancet 364:1489-96. 2004
    In patients who present with clinically isolated syndromes suggestive of multiple sclerosis, interferon beta-1a is effective in delaying evolution to clinically definite disease and in reducing MRI-measured disease activity...
  94. ncbi Real-life impact of early interferon beta therapy in relapsing multiple sclerosis
    M Trojano
    Department of Neurological and Psychiatric Sciences, University of Bari, Italy
    Ann Neurol 66:513-20. 2009
    Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS)...
  95. ncbi Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection
    Bobbie Ann Austin
    Department of Ophthalmology, University of Oklahoma Health Sciences Center, Biomedical Sciences Building, 608 Stanton L Young Boulevard, Oklahoma City, OK 73104, USA
    J Immunol 175:1100-6. 2005
    ....
  96. ncbi Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients
    Miguel Lucas
    Molecular Biology Service of the Virgen Macarena University Hospital, Avda Dr Fedriani 3, 41071 Seville, Spain
    Neurochem Int 42:67-71. 2003
    ..in a cohort of multiple sclerosis (MS) patients undergoing weekly treatment with 30 microg intramuscular interferon beta-1a for 2 years...
  97. ncbi Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis
    Bernhard Hemmer
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Lancet Neurol 4:403-12. 2005
    b>Interferon beta was the first therapy to be approved for the treatment of relapsing-remitting multiple sclerosis (MS) more than 10 years ago...
  98. ncbi Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
    M Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Neurology 65:802-6. 2005
    ..Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment...
  99. ncbi Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy
    R Zivadinov
    Department of Neurology, Buffalo Neuroimaging Analysis Center, The Jacobs Neurological Institute, University at Buffalo, State University of New York, Buffalo, NY, USA
    Mult Scler 13:490-501. 2007
    ..Although neurological deficiencies in MS are primarily due to loss of WM, the clinical significance of GM atrophy has not been fully explored in MS...
  100. ncbi A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex)
    S Mitchell Freedman
    University of North Carolina, Chapel Hill NC, USA
    J Neurosci Nurs 40:350-5. 2008
    ..patient perceptions of using a smaller needle (1-inch, 25-gauge) to administer weekly intramuscular (IM) interferon beta-1 a (IFNbeta-1 a [Avonex]) injections...
  101. pmc Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs
    M Bouloy
    , Institut Pasteur, F-75724 Paris Cedex, France
    J Virol 75:1371-7. 2001
    ..These results demonstrate that the ability of RVFV to inhibit IFN-alpha/beta production correlates with viral virulence and suggest that the accessory protein NSs is an IFN antagonist...

Research Grants64

  1. Ebola VP35 mediated viral mechanisms
    Bin He; Fiscal Year: 2004
    ..abstract_text> ..
  2. The PKCepsilon-regulated oncogenic and tumor suppressor roles of ATF2 in melanoma
    ERIC KIRK LAU; Fiscal Year: 2013
    ..I have found that PKCepsilon phosphorylated ATF2 represses the expression of Interferon Beta 1 (IFNB1) and related downstream targets...
  3. ATF3-Mediated Transcriptional Repression of Interferon-beta
    STEVE LEE WEINSTEIN; Fiscal Year: 2010
    ..The possibility that repression of IFN-? transcription by ATF-3 is caused by histone deacetylation will be tested by examining the acetylation state of IFN-? promoter histones in the presence or absence of ATF-3 by ChlP. ..
  4. Methamphetamine, Stress and SIV: Effects at Blood-Brain Barrier and Lymph Nodes
    John P Capitanio; Fiscal Year: 2010
    ..Relevance ..
  5. Deep Sequencing of Kawasaki Disease Tissues
    Anne H Rowley; Fiscal Year: 2012
    ..Identification of the causative agent of KD would have profound implications for the field, enabling development of a diagnostic test, improved therapies, and ultimately, prevention of this potentially fatal illness of childhood. ..
  6. Bone Marrow Stem Cells: Novel Treatment of Human Glioma
    Frederick F Lang; Fiscal Year: 2010
    ....
  7. Elucidating the mechanisms that mediate the effects of lipoic acid in MS
    Sonemany Salinthone; Fiscal Year: 2013
    ..Mechanistic understanding of the cAMP-mediated action of LA will provide guidance in issues relating to drug delivery, dosage requirement, and potentially even in the diagnosis or treatment of different forms or stages of MS. ..
  8. Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition
    LAWRENCE MARC PFEFFER; Fiscal Year: 2013
    ..In this proposal we plan to pursue a strategy to treat malignant glioma with the potent antitumor cytokine, interferon beta (IFN2).
  9. ACE engineered MSCs as a multidrug-delivery platform for breast cancer therapy
    EDWARD LEON PERKINS; Fiscal Year: 2013
    ..we propose to bioengineer MSCs with an ACE chromosome in order to express, on demand, two anti-tumor factors-interferon beta (IFNb) and the EGFR/MET receptor antagonist decorin (DCN)...
  10. Molecular Stratification of Multiple Sclerosis and Associated Neuro-autoimmune Di
    Robert C Axtell; Fiscal Year: 2012
    ..The major goal of this proposal is to determine the mode of action of IFN-beta therapy and identify biomarkers that can predict responsiveness to this treatment. ..
  11. Innate Immunity and Hepatitis C Virus Infection
    Ratna B Ray; Fiscal Year: 2013
    ..We have recently shown that HCV infection in cell culture activates interferon beta (IFN-2) expression and induces autophagy...
  12. Molecular Stratification of Multiple Sclerosis and Associated Neuro-autoimmune Di
    Robert C Axtell; Fiscal Year: 2013
    ..The proposed research plan, training development and environment at Stanford will be highly conducive for my transition to an independent faculty. ..
  13. Semaphorin 3F: Structure, Function, and Anti-Metastatic Activity
    Diane Renee Bielenberg; Fiscal Year: 2010
    ..Most of all, a Howard Temin Award would enable the continuation of this research project toward the ultimate goal of long-term stable disease. ..
  14. Ulcerative Colitis - Regulation of the IL-13 Receptor System
    Peter Mannon; Fiscal Year: 2013
    ..The results will be applicable to other mucosal inflammatory diseases like allergic asthma and eosinophilic esophagitis where IL-13 also drives disease and new therapies targeting IL-13 are needed. ..
  15. Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing
    George Cox; Fiscal Year: 2009
    ..This protein may provide Multiple Sclerosis patients with a more effective and more convenient therapy for the treatment their disease. ..
  16. Extension of Combination Therapy for Multiple Sclerosis (eCombiRx)
    Fred D Lublin; Fiscal Year: 2012
    ..is a randomized, double blind, placebo controlled, multi-center randomized study of the efficacy of combining interferon beta-la (IFN) and glatiramer acetate (GA) compared to either agent alone as primary therapy for relapsing-..
  17. INTERFERON RECEPTORS IN ORGAN TRANSPLANTATION
    Verna Gibbs; Fiscal Year: 1999
    ..The information generated from these studies may provide a rational basis for the development of agonists and antagonists which may be clinically useful in preventing acute graft rejection and chronic graft failure. ..
  18. PATHOBIOLOGY OF HEPATITIS B VIRUS
    ROBERT SCHLOEMER; Fiscal Year: 1990
    ..In this manner, information concerning the interaction between hepatitis B virus and interferon can be obtained and may shed some light on the fact that the effectiveness of treatment of chronic hepatitis with interferon is so variable...
  19. GENE-BASED THERAPIES AND IMAGING OF MALIGNANT GLIOMAS
    Kevin Judy; Fiscal Year: 2003
    ..We believe that this study will have important implications for brain tumor gene therapies in general and provide a new clinical modality for assessing gene transfer. ..
  20. PULSE THERAPY TRIAL IN BETA INTERFERON RESISTANT ACTIVE
    Derek Smith; Fiscal Year: 2003
    ..We have found that the treatment of MS patients with some of these agents results in a number of changes, notably increases of IL-4 secretion associated with eosinophilia and decreases in IL-12. ..
  21. Visualizing Interferon-beta Induction In Vivo
    Joan Durbin; Fiscal Year: 2009
    ..These reagents will allow virologists to study the ability of many different viruses to activate and/or suppress type I IFN production in vivo and in vitro. ..
  22. NOVEL E1 CELL LINE FOR RCA-FREE ADENOVIRAL GENE THERAPY
    Richard Peluso; Fiscal Year: 2001
    ..This cell line will be used to produce adenoviral vectors to deliver INF-beta as an anti-tumor drug and thereby decrease the overall cost of these diseases to the national healthcare system. ..
  23. The Effects of Interferons on Anthrax Toxicity
    Andrew Larner; Fiscal Year: 2005
    ..We present evidence that treatment of macrophages with interferon beta (IFNbeta) or interferon gamma (IFNgamma) promotes survival of macrophages after LT exposure...
  24. A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS
    DOROTHY CROSS; Fiscal Year: 2007
    ..Parks and Naismith, and PI will be able to focus 30% more time on investigator-initiated trials and mentoring junior colleagues. ..
  25. MECHANISMS OF IMMUNOLOGICALLY MEDIATED FATIGUE
    PHILIP PETERSON; Fiscal Year: 2001
    ..These studies will enhance our understanding of the pathophysiology of immunologically mediated fatigue and will foster the development of new treatment strategies, particularly for patients with CFS. ..
  26. LONG-ACTING BETA INTERFERON FOR MULTIPLE SCLEROSIS
    George Cox; Fiscal Year: 2001
    ..Additional expected benefits include improved drug efficacy and reduced toxicity, which will significantly enhance patient quality of life. ..
  27. Rational Optimization of Protein Solubility
    JOHN DESJARLAIS; Fiscal Year: 2003
    ..Protein Design Automation(r) (PDATM), to improve the solubility of an important protein therapeutic, interferon beta. Currently, interferon beta is the primary treatment for multiple sclerosis...
  28. IFN-BETA CONTROL OF TH CELL DIFFERENTIATION/FUNCTION
    GIJSBERT VAN SEVENTER; Fiscal Year: 2003
    ....
  29. MRI T2 shortening ('blackT2') in multiple sclerosis
    Rohit Bakshi; Fiscal Year: 2003
    ..Alternatively, if iron accumulation is a disease epiphenomenon, then BT2 could be used as a noninvasive marker of brain degeneration. ..
  30. Treatment of Multiple Sclerosis
    Anthony Reder; Fiscal Year: 2009
    ..of Health Studies and its K30 program, and educate fellows in trial design, statistics, and all neurologic aspects of MS. ..
  31. Electroporation-mediated Gene-based Interferon-beta
    Claire Evans; Fiscal Year: 2006
    ..The proposed studies will evaluate the potential of a gene-based interferon-beta therapy for atherosclerosis, and thus will address a very critical need in current medical care. [unreadable] [unreadable] [unreadable]..
  32. GROWTH/DIFFERENTIATION FACTORS IN NORMAL/IMMUNE B CELLS
    ROBERT ASHMAN; Fiscal Year: 1992
    ..early biochemical and cell surface events in activation, we will discover whether the differentiation factor interferon beta 2, the high and low molecular weight B cell growth factors, and anti-CDw40, utilize any of the known signal ..
  33. Electroporation-Mediated Gene Therapy with IFN-b for MS
    Claire Evans; Fiscal Year: 2005
    ..These studies will set the stage for formal safety/toxicology evaluations and Phase I human studies, with the ultimate goal of providing an effective gene-based IFN-beta therapy for MS. ..
  34. Immunomodulation in Multiple Sclerosis by Interferon B
    Jorge Oksenberg; Fiscal Year: 2005
    ..b>Interferon beta (IFN¿) has been shown to decrease clinical relapses, reduce brain MRI activity, and slow progression of ..
  35. TGF-beta 1-regulated IL-8 expression in prostate cancer
    Zhongyun Dong; Fiscal Year: 2007
    ..TGF-beta1-stimulated IL-8 expression and IL-8 gene promoter activation in cells lacking the three TGF-beta signaling pathways as well as transcription factors involved will be determined. ..
  36. PRDI-BF1 and histone methyltransferase in lymphoma
    Kenneth Wright; Fiscal Year: 2009
    ..Thus this proposal will shed new light on the events occurring during differentiation and may indicate new targets to affect the growth and persistence of lymphomas. ..
  37. DEVELOP MULTIPLE SCLEROSIS TREATMENT USING PHAGE DISPLAY
    Jasmin Enright; Fiscal Year: 1999
    ..In future experiments, the molecules that are isolated will be tested in an established primate model of MS, and then will be developed for clinical evaluation in patients. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  38. Role of interferon beta in hypoxic intestinal epithelium
    Nancy Louis; Fiscal Year: 2006
    Through study of the interaction between interferon beta (IFNbeta) and hypoxia-inducible factor 1 (HIF-1), important advances will be made in understanding epithelial regulation of the exposure of the immune system to contents of the ..
  39. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. [unreadable] [unreadable]..
  40. Case/Cleveland Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2004
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  41. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  42. IM RECOMBINANT BETA INTERFERON AS TREATMENT FOR MS
    Lawrence Jacobs; Fiscal Year: 1993
    ..If the results of this study are positive, then rFIN-B may be widely employed in the future as a practicle clinical too in the treatment of MS...
  43. THE ROLE OF IRF PROTEINS IN GENE TRANSCRIPTION
    Aneel Aggarwal; Fiscal Year: 2009
    ..I. PU.1 will be phosphorylated in vitro by casein kinase II prior to crystallization. Together, these aims explore the specificity and cooperativity of these IRFs, and the role of phosphorylation and autoinhibitory elements. ..
  44. Role of the Fragilis Proteins in the Immune Response
    JOHN WEIS; Fiscal Year: 2005
    The fragilis gene family represents a relatively unknown group of interferon beta inducible genes/gene products who have been implicated in the down modulation of the immune response...
  45. Innate Immune Responses in Reovirus Infection
    GEOFFREY HOLM; Fiscal Year: 2007
    ..Together, these studies will provide new insights into the interface between the innate antiviral response, cell death pathways, and viral disease pathogenesis. [unreadable] [unreadable] [unreadable]..
  46. The Roles of IRF-3 in the Cellular Response to Viral Infection
    Peter Howley; Fiscal Year: 2007
    ..We will explore this pathway and examine the mechanisms by which some viruses inactivate this pathway for the replication of the virus and the survival of the infected cell. ..
  47. Using the Internet to Improve Patient's Self-Management of Chronic Illness
    Deborah Miller; Fiscal Year: 2006
    ..The utilization analysis will allow us to identify the incremental benefit of the comprehensive system compared to the secure system and to determine where there greatest savings in overall cost of care is gained. ..
  48. Innate immune evasion and/or antagonism by eastern equine encephalitis virus
    KATHERINE RYMAN; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  49. Pregnancy and the Modulation of Multiple Sclerosis
    Annette Langer Gould; Fiscal Year: 2006
    ..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
  50. Targeting innate immunity to prevent CNS injury in neonatal meningitis
    Timothy Vartanian; Fiscal Year: 2007
    ..Hypothesis: In GBS (live) meningitis treated with standard antimicrobial therapy, neuronal injury will be limited in animals lacking functional TLR2 or MyD88. [unreadable] [unreadable] [unreadable]..
  51. INCLUSION BODY MYOSITIS: PILOT STUDY OF B-INTERFERON 1A
    Rabi Tawil; Fiscal Year: 2002
    ..The testing methods have been validated by the investigators in other studies of muscle disease. The information obtained in this study will be essential for the effective design and conduct of pivotal trials in IBM. ..
  52. NEUREGULINS IN OLIGODENDROCYTE DEVELOPMENT & MYELINATION
    Timothy Vartanian; Fiscal Year: 2002
    ..The physical and functional association of activated neuregulin receptors with intracellular signaling molecules will be studied in cells of the oligodendrocyte lineage. ..
  53. Caveolin-1/lGF-IR Interactions in Oligodendrocytes
    Daniel Mikol; Fiscal Year: 2004
    ..Understanding the interplay between the IGF-IR and caveolin-1 and their control of OLG phenotype will provide insight into the molecular basis of myelination by OLGs and, hopefully, guide new treatments for MS. ..
  54. Borrelia lipoproteins with the cerebral microcirculation
    Diego Cadavid; Fiscal Year: 2007
    ..2. Investigate whether Vspl enters BMEC. 3. Determine whether Vspl crosses BMEC barriers. 4. Identify the structural features that mediate the interaction of Vspl with BMEC. [unreadable] [unreadable]..
  55. NEUROIMMUNOLOGY OF AED IN OCULAR HSV-1 INFECTION
    Daniel Carr; Fiscal Year: 2001
    ..abstract_text> ..
  56. FRZB PROFILES AS OSTEOARTHRITIS BIOMARKERS
    MARY CORR; Fiscal Year: 2004
    ..The results of these studies will both contribute to, and will utilize, the resources of the OA biomarker consortium. ..
  57. INTERFERON-B AND COPOLYMER-I IN MULTIPLE SCLEROSIS.
    Suhayl Dhib Jalbut; Fiscal Year: 2003
    ..The proposed research could help identify components of the immunologic network in MS that are associated with response to treatment, and therefore help in the design of more effective future therapies. ..
  58. Anti-Viral Gene Delivery in the Nervous System
    Daniel Carr; Fiscal Year: 2005
    ..abstract_text> ..
  59. NATURAL KILLER CELL GROWTH AND DEVELOPMENT
    Christine Biron; Fiscal Year: 2008
    ..The work promises to continue to advance basic immunological knowledge and provide insights for therapy. ..
  60. The Role of CXCL9 in Genital HSV-2 Infection
    Daniel Carr; Fiscal Year: 2009
    ..g., vaccine or gene transfer) to reduce the incidence of infection or reduce the capacity of latent virus to reactivate. ..
  61. Mucosal Immunotherapy in a mouse model of Alzheimer's Disease
    Howard L Weiner; Fiscal Year: 2010
    ..In this aim, we will investigate long term mucosal strategy to prevent and treat APP Tg mice using unique mucosal adjuvant combination given nasally and their ability to enhance amyloid clearance. ..
  62. IMMUNOREGULATORY T CELLS IN MULTIPLE SCLEROSIS
    Howard Weiner; Fiscal Year: 2005
    ..Our investigations will be greatly facilitated by our new Multiple Sclerosis Center with a large patient base and a dedicated MS MRI magnet and image analysis laboratory. ..